231 related articles for article (PubMed ID: 31203490)
1. Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.
Han M; Sun D
J Comput Aided Mol Des; 2019 Jul; 33(7):689-698. PubMed ID: 31203490
[TBL] [Abstract][Full Text] [Related]
2. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
3. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
4. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
5. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
[TBL] [Abstract][Full Text] [Related]
7. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Anastassiadis T; Deacon SW; Devarajan K; Ma H; Peterson JR
Nat Biotechnol; 2011 Oct; 29(11):1039-45. PubMed ID: 22037377
[TBL] [Abstract][Full Text] [Related]
9. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in designing substrate-competitive protein kinase inhibitors.
Han KC; Kim SY; Yang EG
Curr Pharm Des; 2012; 18(20):2875-82. PubMed ID: 22571656
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1.
Gupta PP; Bastikar VA; Kuciauskas D; Kothari SL; Cicenas J; Valius M
Med Oncol; 2017 Sep; 34(10):176. PubMed ID: 28879492
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Shen M; Yu H; Li Y; Li P; Pan P; Zhou S; Zhang L; Li S; Lee SM; Hou T
Mol Biosyst; 2013 Jun; 9(6):1511-21. PubMed ID: 23549429
[TBL] [Abstract][Full Text] [Related]
14. Consensus scoring approach to identify the inhibitors of AMP-activated protein kinase α2 with virtual screening.
Park H; Eom JW; Kim YH
J Chem Inf Model; 2014 Jul; 54(7):2139-46. PubMed ID: 24915156
[TBL] [Abstract][Full Text] [Related]
15. In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.
Tanneeru K; Balla AR; Guruprasad L
J Biomol Struct Dyn; 2015; 33(8):1710-9. PubMed ID: 25245460
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase inhibitors: contributions from structure to clinical compounds.
Johnson LN
Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866
[TBL] [Abstract][Full Text] [Related]
17. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
[TBL] [Abstract][Full Text] [Related]
18. Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.
Tasler S; Müller O; Wieber T; Herz T; Pegoraro S; Saeb W; Lang M; Krauss R; Totzke F; Zirrgiebel U; Ehlert JE; Kubbutat MH; Schächtele C
Bioorg Med Chem; 2009 Sep; 17(18):6728-37. PubMed ID: 19692247
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM-GBSA calculation.
Du J; Sun H; Xi L; Li J; Yang Y; Liu H; Yao X
J Comput Chem; 2011 Oct; 32(13):2800-9. PubMed ID: 21717478
[TBL] [Abstract][Full Text] [Related]
20. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
